Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS2401 in Advanced Prostate Cancer
NCT07869888Phase 1Not yet recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Nov 2026
- Primary completion
- Mar 2029
01
Overview
Phase 1, open-label, single-arm trial of QLS2401 in prostate cancer (PCa), sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Maximum Administered Dose at 3 weeks and 4 more. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
QLS2401
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07869888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07869888.